Imperial College London
Portrait Picture

DrMelpomeniKalofonou

Faculty of Engineering, Department of Electrical and Electronic Engineering

Research Fellow in Cancer Technology
 
 
 
//

Contact

 

+44 (0)20 7594 1594m.kalofonou Website CV

 
 
//

Location

 

B420C - Centre for Bio-Inspired Technology (CBIT)Bessemer BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Dimitrakopoulos:2019,
author = {Dimitrakopoulos, F-I and Kottorou, A and Antonacopoulou, A and Nikolakopoulos, A and Panagopoulos, N and Kalofonou, M and Dougenis, D and Koutras, A and Makatsoris, T and Tzelepi, V and Kalofonos, H},
pages = {8537--8537},
publisher = {American Society of Clinical Oncology},
title = {Association of BAFFR expression in CAFs with overall survival and response to platinum-based chemotherapy in NSCLC},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AB  - Background: Β-cell activating factor receptor (BAFFR) is a surface receptor, which leads to activation of the Nuclear Factor-kappaB (NF-κB) alternative pathway, a pathway with an important role in non-small cell lung cancer (NSCLC). In addition, cancer associated fibroblasts (CAFs) are major players of the tumor microenvironment promoting NSCLC. The aim of this study was to assess the possible associations of BAFFR expression in CAFs with response to first-line chemotherapy doublet and clinical outcome of NSCLC patients. Methods: Immunohistochemical analysis of BAFFR expression on CAFs was performed on tumor and tumor-adjacent formalin fixed and paraffin embedded tissue samples from 124 operated patients with NSCLC. Patients were under follow-up for at least 60 months, while response to chemotherapy was evaluated in patients who relapsed during this period. Results: BAFFR expression, which was noted exclusively in the cytoplasm of CAFs, was associated with OS only in patients with no infiltration of regional lymph nodes. Higher expression levels of BAFFR in CAFs were related to worse 2-, 3- and 5-year survival (P = 0.015, P = 0.027 and P = 0.040, respectively). This finding persisted after multivariate analysis with age, gender, histological subtype, histological differentiation and disease stage as coefficients (P = 0.009; HR, 2.734; 95% CI, 1.283-5.828). In addition, response to first line chemotherapy was associated with BAFFR expression in CAFs (P = 0.025). Patients who progressed had lower BAFFR levels. Furthermore, BAFFR expression in CAFs was associated with patients’ age. In particular, older patients had higher expression of BAFFR compared to patients younger than 55 years (P = 0.010). Additionally, carcinomas with better differentiation had lower expression of BAFFR in CAFs (P = 0.005). Finally, BAFFR expression in CAFs was related to development of metastatic disease (P = 0.033) and particularly in liver (P = 0,017) and in bones (P = 0.00
AU  - Dimitrakopoulos,F-I
AU  - Kottorou,A
AU  - Antonacopoulou,A
AU  - Nikolakopoulos,A
AU  - Panagopoulos,N
AU  - Kalofonou,M
AU  - Dougenis,D
AU  - Koutras,A
AU  - Makatsoris,T
AU  - Tzelepi,V
AU  - Kalofonos,H
EP  - 8537
PB  - American Society of Clinical Oncology
PY  - 2019///
SN  - 0732-183X
SP  - 8537
TI  - Association of BAFFR expression in CAFs with overall survival and response to platinum-based chemotherapy in NSCLC
ER  -
Download